An Albumin-Bilirubin (ALBI) Grade–based Prognostic Model For Patients With Hepatocellular Carcinoma Within Milan Criteria

This study aimed to develop and validate an albumin-bilirubin (ALBI) grade–based prognostic model to stratify survival in patients within Milan criteria undergoing nontransplant therapy. Patients and Methods: A total of 1655 patients were assigned into the derivation and validation cohort according to treatment modalities. Multivariate analysis was used to identify independent predictors of survival in the derivation cohort. An ALBI-based model was evaluated in the validation cohort. Results: In the Cox multivariate model, age 65 years or older (hazard ratio [HR]=1.576, P100 ng/mL (HR=1.671, P
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Gastrointestinal Source Type: research